Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 2. Please see detailed guidance ...

One of the secrets to living a longer, better life is beating in our chests. An estimated 80% of cardiovascular disease (CVD) can be prevented with lifestyle changes and available tools, yet it ...

Acute myeloid leukemia (AML), the most common form of acute leukemia in adults, is a cancer of the blood and bone marrow. Prognosis and survival rate may depend on numerous factors.

Reshema Kemps-Polanco is Executive Vice President and Chief Commercial Officer, Novartis US, responsible for the expansion of medicines across oncology, immunology, neurology, and cardiovascular, ...

At Novartis, we reimagine medicine to improve and extend people’s lives. This includes discovering and developing breakthrough therapies and finding new ways to deliver these treatments to as many ...

. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result ...

Basel, January 13, 2025 – Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto ...

Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025 DTP offering to expand to other appropriate products; ...

Acquisition of Kate Therapeutics enhances and strengthens Novartis strategic priorities in gene therapy and neuroscience innovation Transaction includes enabling technology platforms and therapeutic ...

Behind every transformational leader is a remarkable story. For Reshema Kemps-Polanco, Chief Commercial Officer of Novartis US, it's a journey that weaves together military discipline, a sharp ...

Manju Ujjini, Head of Lead Discovery for our Global Health Biomedical Research group, discusses what’s next for his team in drug discovery Manjunatha (“Manju”) Ujjini aims to discover medicines for ...

Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42. Although artificial intelligence has been ...